Local company to acquire South African pharmaceutical manufacturing facility from global major pharm
100% black-owned local pharmaceutical manufacturer is born
Pharmaceutical and medical technologies company, Kiara Health, has signed an agreement with Sandoz South Africa to acquire its manufacturing facility in South Africa. The plant currently manufactures a range of products which are widely used in both the public and private sectors.
The transaction supports Kiara Health’s vision to make world-class pharmaceutical products accessible to all patients and to further develop South Africa’s pharmaceutical manufacturing capabilities in what is considered a critical sector for the economic and social well-being in the country.
The transaction is expected to be finalised in the coming months upon completion of regulatory approvals and customary closing conditions, whereupon the site ownership and operations will transfer to Kiara Health.
“The acquisition of the Sandoz South Africa manufacturing facility, will see the transfer of the company’s state-of-the-art manufacturing site in Spartan, located just outside Johannesburg, as well as its expertise, know-how and technology, to Kiara Health. In addition, Kiara is acquiring a portfolio of marketing authorisations for various therapeutic categories.
This will be synergistic with the Kiara pipeline and add more value to our commercial basket,” says Dr Skhumbuzo Ngozwana, Chief Executive Officer of Kiara Health.
This momentous development heralds the birth of a 100% black-owned South African pharmaceutical manufacturer which will be amongst the leading single-site pharmaceutical manufacturing operations, by staff complement and asset size, in South Africa.
Kiara Health is a BBEEE owned and controlled healthcare company, led by leading black pharmaceutical industry professionals that aims to improve access to essential healthcare products and technologies, at affordable prices, to serve Africa’s current and emerging healthcare needs. The attainment of select OTC products from the Sandoz stable allows Kiara Health to compete in the fast-growing self-medication market.
“The manufacturing facility in Spartan, along with the dedicated team of employees who we welcome from Sandoz South Africa, will be invaluable in scaling our operations and increasing our product range, enabling Kiara Health to bring affordable medicines to the market. This is significant as it provides additional security in the supply of essential medicines to our target markets” added Dr Ngozwana.
As part of the transaction, the parties have also committed to a long-term supply contract guaranteeing continuous supply to Sandoz South Africa of products currently manufactured at the facility. The acquisition ideally positions Kiara Health to meet the country’s endeavours to improve healthcare outcomes in the public and private sector.
The acquisition of certain OTC products from the Sandoz stable allows Kiara Health to compete in the fast-growing self-medication market.
“We would like to thank Novartis and Sandoz for the belief they have shown in Kiara and its vision and for the tangible contribution they have committed to make to the economic transformation of South Africa’s pharmaceutical sector.
We believe the Spartan site provides a wonderful platform for the growth of a homegrown African pharmaceutical champion and ultimately, this acquisition brings us a step closer to making an appreciable contribution to the overall improvement in the quality of life in the markets we serve,” Dr Ngozwana concluded.